1995
DOI: 10.1001/jama.274.17.1353
|View full text |Cite
|
Sign up to set email alerts
|

High-dose nicotine patch therapy. Percentage of replacement and smoking cessation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
114
2
2

Year Published

2002
2002
2011
2011

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 112 publications
(124 citation statements)
references
References 0 publications
6
114
2
2
Order By: Relevance
“…However, when using the CYP2A6 phenotype (3HC/COT), the data indicate better quit rates for slow metabolizers relative to fast metabolizers on the nicotine patch (Lerman et al, submitted), as would be expected given their higher levels of nicotine. 33,55 The mean 3HC/COT ratio of the slow metabolizers was approximately 50% of that of the normal metabolizers (Figure 1). Those with a CYP2A6 intermediate metabolizer genotype, predicting approximately 75% remaining activity, were indeed intermediate and were not significantly different from either the slow or normal metabolizers.…”
Section: Discussionmentioning
confidence: 98%
See 1 more Smart Citation
“…However, when using the CYP2A6 phenotype (3HC/COT), the data indicate better quit rates for slow metabolizers relative to fast metabolizers on the nicotine patch (Lerman et al, submitted), as would be expected given their higher levels of nicotine. 33,55 The mean 3HC/COT ratio of the slow metabolizers was approximately 50% of that of the normal metabolizers (Figure 1). Those with a CYP2A6 intermediate metabolizer genotype, predicting approximately 75% remaining activity, were indeed intermediate and were not significantly different from either the slow or normal metabolizers.…”
Section: Discussionmentioning
confidence: 98%
“…This is important to study as increasing the amount of nicotine replaced by NRT has been shown to improve abstinence rates and alleviate withdrawal symptoms, particularly on the nicotine patch. 33,34 We investigated four CYP2A6 genetic variants, CYP2A6*2, CYP2A6*4, CYP2A6*9A and CYP2A6* 12A, which are common among Caucasians, 15 and have a known detrimental impact on enzyme function. 4,11,[35][36][37] To assess whether CYP2A6 genetic variants affect enzyme activity, smoking behaviours and plasma levels from treatments, CYP2A6 activity groups were defined based on the impact of each CYP2A6 allele.…”
Section: Introductionmentioning
confidence: 99%
“…33 The DES was developed using reports describing the effects of nicotine, caffeine, and other drugs. 30,34 The scale consisted of 17 items: "Do you feel any drug effects? ", "Do you like the drug effects?…”
Section: Outcome Measuresmentioning
confidence: 99%
“…Second-line pharmacotherapies to consider are clonidine and nortriptyline. 63 There is also evidence that combined NRT (e.g., combination patch and gum, 63 high-dose NRT, 65 or combined bupropion and NRT 66 ) increases long-term abstinence rates. Therefore, these medication options should be considered carefully.…”
Section: Recommendations For Nicotine Dependence Treatmentmentioning
confidence: 99%